Rousset Rebecca Z, Claessen Thomas, van Harten Argonde C, Lemstra Afina W, Pijnenburg Yolande A L, van der Flier Wiesje M, den Braber Anouk, Jeromin Andreas, Verberk Inge M W, Teunissen Charlotte E
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience De Boelelaan Amsterdam The Netherlands.
Alzheimer Center Department of Neurology Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience De Boelelaan Amsterdam The Netherlands.
Alzheimers Dement (Amst). 2024 Nov 23;16(4):e70003. doi: 10.1002/dad2.70003. eCollection 2024 Oct-Dec.
Plasma phosphorylated tau-217 (p-tau217) and neurofilament light (NfL) can differentiate between different dementias in selected cohorts. We aim to test the discrimination potential of these markers in a real-world cohort.
We measured p-tau217 (ALZpath) and NfL (Quanterix) in 415 (unselected) consecutive memory clinic patients. Biomarker levels were dichotomized as low/high to create four biomarker profiles based on p-tau217 and NfL levels.
p-Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD). Low p-tau217/low NfL was associated mostly with non-neurological diagnoses (79%), and high p-tau217/low NfL indicated AD pathology at any stage (84%). Low p-tau217/high NfL indicated FTD (38%) and high p-tau217/high NfL indicated AD dementia (87%).
p-Tau217 can identify AD pathology at any disease stage. NfL can differentiate FTD from other diagnoses (e.g., AD dementia). Plasma p-tau217 and NfL can support clinical decision-making, and we suggest using them as complements to standard clinical assessment.
Phosphorylated tau-2017 (p-tau217) can detect Alzheimer's disease (AD) across the clinical continuum.Neurofilament light (NfL) can differentiate frontotemporal dementia (FTD) from other diagnoses (AD dementia, dementia with Lewy bodies [DLB], and Psychiatry).p-Tau217 may detect AD co-pathology in other diseases or dementia types (e.g., DLB).p-Tau217 and NfL show potential for clinical implementation.
血浆磷酸化tau-217（p-tau217）和神经丝轻链（NfL）可在特定队列中区分不同类型的痴呆症。我们旨在测试这些标志物在真实世界队列中的鉴别潜力。
我们对415名（未经过筛选）连续就诊于记忆门诊的患者测量了p-tau217（ALZpath法）和NfL（Quanterix法）。根据p-tau217和NfL水平将生物标志物水平分为低/高，从而创建四种生物标志物谱。
阿尔茨海默病（AD）痴呆患者的p-tau217水平最高，而额颞叶痴呆（FTD）患者的NfL水平最高。低p-tau217/低NfL主要与非神经学诊断相关（79%），高p-tau217/低NfL表明在任何阶段均存在AD病理（84%）。低p-tau217/高NfL表明为FTD（38%），高p-tau217/高NfL表明为AD痴呆（87%）。
p-tau217可在任何疾病阶段识别AD病理。NfL可将FTD与其他诊断（如AD痴呆）区分开来。血浆p-tau217和NfL可辅助临床决策，我们建议将它们用作标准临床评估的补充。
磷酸化tau-2017（p-tau217）可在整个临床病程中检测出阿尔茨海默病（AD）。神经丝轻链（NfL）可将额颞叶痴呆（FTD）与其他诊断（AD痴呆、路易体痴呆[DLB]和精神疾病）区分开来。p-tau217可能在其他疾病或痴呆类型（如DLB）中检测出AD共病病理。p-tau217和NfL显示出临床应用潜力。
